TABLE 3

Characteristics of Acute Diarrhea Trials

ReferenceCountryZinc SupplementZinc DosageZinc/Control Group, NAge, mo
Sachdev et al17 (1988)IndiaSulfate20 mg25/256–18
Sazawal et al31 (1995)IndiaGluconate20 mg456/4816–35
Roy et al30 (1997)BangladeshAcetate20 mg57/543–24
Faruque et al27 (1999)BangladeshAcetate14/40 mg343/3416–23
Hidayat et al28 (1998)IndonesiaAcetate4/5 mg/kg739/6593–25
Dutta et al26 (2000)IndiaSulfate40 mg44/363–24
Strand et al32 (2002)NepalGluconate15/30 mg445/4496–35
Bahl et al23 (2002)aIndiaGluconate15/30 mg404/4016–35
Al-Sonboli et al22 (2003)BrazilSulfate22.5/45 mg37/373–60
Polat et al29 (2003)bTurkeySulfate20 mg92/902–29
Bhatnagar et al24 (2004)IndiaSulfate15/30 mg143/1443–36
Valery et al19 (2005)cAustraliaSulfate20/40 mg107/1080–11, 12–23, ≥24
Patel et al20 (2005)IndiaSulfate/copper sulfate40 mg/5 mg102/986–59
Brooks et al25 (2005)dBangladeshAcetate20 mg86/891–6
Baqui et al15 (2002)BangladeshAcetate20 mg3974/40963–59
Fischer Walker et al16 (2006)Pakistan, Ethiopia, IndiaSulfate10 mg554/5561–5
  • a Three study groups were examined (control, zinc syrup, and zinc/ORS). We included only those who received zinc syrup or a control.

  • b Four study groups were examined: low/normal zinc in 2 intervention groups and low/normal zinc in 2 control groups. We combined the groups into either intervention or control, without excluding those with low zinc levels.

  • c Children up to 11 years of age were included; however, 45.1% (97 of 215) were 0 to 11 months of age; 38.1% (82 of 215) were 12 to 23 months; and only 16.8% (36 of 215) were ≥24 months. All study participants were included in our analyses.

  • d Three groups were used (control, 5 mg of zinc acetate, and 20 mg of zinc acetate). We examined only those who used 20 mg of zinc versus control subjects. Brooks et al enrolled only male children.